You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. New generation of catheters for treatment of atrial fibrillation

    SBC: NOCTURNAL PRODUCT DEVELOPMENT, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Atrial fibrillation AF remains the most commonly occurring cardiac arrhythmia It is associated with a lower quality of life and a higher rate of morbidity andamp mortality primarily due to poor hemodynamics and often stroke One of the main options to treat atrial fibrillation is to ablate abnormal sources of electrical activity using percutaneous radiofrequ ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Developing Therapeutics That Target RAD To Treat Leukemia and Lymphoma

    SBC: Cyteir Therapeutics, Inc.            Topic: NCI

    DESCRIPTION provided by applicant Genomic instability is a hallmark of cancer and represents a targetable vulnerability yet is underdeveloped as a therapeutic area The central goal of this Phase program is to complete the early preclinical development of a new class of new cancer therapeutics that uniquely target RAD delivering effective cancer cell selective therapy in subsets of bioma ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Therapeutics for inflammatory bowel disease from the microbiome

    SBC: SYMBIOTIX BIOTHERAPIES, INC.            Topic: 300

    PROJECT SUMMARY ABSTRACT Interactions between the gut microbiome and the immune system have been linked to inflammatory bowel disease IBD IBD is a chronic and progressive gastrointestinal disease characterized by uncontrolled activation of the intestinal immune system resulting in severe medical complications affecting over million patients in the United States It is a disease of high u ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NIDDK

    DESCRIPTION provided by applicant Non alcoholic steatohepatitis NASH is characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosis and cirrhosis and high mortality rates NASH is frequently associated with other common metabolic abnormalities such as insulin resistance and visceral obesity Liver transplantation is curren ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. The CellRaft AIR System Workflow Automation for Stem Cell Isolation and Recovery

    SBC: Cell Microsystems, Inc.            Topic: 200

    DESCRIPTION provided by applicant Stem cell research is an emerging field with the promise of creating dramatic new approaches for disease treatment and drug discovery The research and regenerative medicine market space for stem cells is one of the most dynamic areas in the life science industry today Globally the stem cell market is growing at a CAGR of and will reach an approximate ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Development of PAR Pepducins for the Treatment of Atopic Dermatitis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NIAMS

    DESCRIPTION provided by applicant Atopic dermatitis AD or severe eczema is a very common life long skin disease with of adults in the US requiring systemic therapy Clinical manifestations of AD include multiple inflamed lesions erosions accompanied by lichenification thick leathery skin fibrotic papules and severely dry skin with increased susceptibility to infection A major uncont ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Anti-biofilm agents for the treatment of pulmonary infection in cystic fibrosis p

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The leading cause of mortality in patients with cystic fibrosis CF is pulmonary failure from lung infections and the predominant organism isolated from these infections is the bacterium Pseudomonas aeruginosa Lung infections of CF patients persist over the lifetime of the patients and are impossible to eradicate due to the ability of bacteria to form biofi ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. New Class of Bright Sharp Tunable Near Infrared Fluorophores for Flow Cytometry

    SBC: Nirvana Sciences, Inc.            Topic: R

    DESCRIPTION provided by applicant Polychromatic flow cytometry FC is one of the most powerful analytical techniques routinely used by both basic research and clinical diagnostics laboratories for the immunological categorization of cells Dyes used for FC typically exhibit broad fluorescent emission bands with full width at half maximum fwhm values of nm This limits the maximum numbe ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. CardioPort to Enable Intracardiac Beating Heart and Minimally Invasive Open Heart Surgery

    SBC: Nido Surgical, Inc            Topic: NHLBI

    DESCRIPTIONprovided by applicantThe goal of this Fast Track STTR project is to develop a novel CardioPortTM surgical device that will enable minimally invasive beating heart repair without use of cardiopulmonary bypassCPBThere is a critical unmet need for new instruments to improve the surgical repair of heart defects in childrenCurrent best surgical practices involve either open heart surgery wit ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Brain penetrant Hsp90 inhibitors for Alzheimer's disease

    SBC: YUMA THERAPEUTICS CORPORAITON            Topic: NIA

    DESCRIPTION provided by applicant Neurodegeneration in Alzheimerandapos s disease AD may result from deposition of A as plaques in brain tissue However less effort has been made to elucidate the role of tau containing neurofibrillary tangles NFTs in AD Accumulating evidence suggests that tau containing NFTs is an important component in the initiation and progression of AD and other neu ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government